511
Participants
Start Date
August 31, 2008
Primary Completion Date
July 31, 2009
Study Completion Date
July 31, 2009
2.5% imiquimod cream
2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
3.75% imiquimod cream
3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
Placebo cream
Placebo cream applied daily to wart areas for up to 8 weeks
University Urology Associates, New York
Boro Park ObGyn, New York
The Clinical Trial Center, Jenkintown
CARE-ID, Annandale
Tidewater Clinical Reseach, Virginia Beach
Independence Family Medicine Clinical Research, Virginia Beach
Piedmont Medical Research, Winston-Salem
Crescent Medical Research, Salisbury
Palmetto Clinical Research, Greer
PMI Health Research Group, Atlanta
Atlanta Women's Research Institute, Atlanta
Altus Research, Lake Worth
Alpha Clinical Research, Clarksville
Tennessee Women's Care, Nashville
Adams Patterson Gynecology and Obstetrics, Memphis
Complete Healthcare for Women, Columbus
Rapid Medical Research, Cleveland
Wright State University, Dayton
Valley Medical Center, Flint
Women's OB/GYN, Saginaw
Howard Brown, Chicago
Altman Dermatology Associates, Arlington Heights
Clayton Research Institute, St Louis
NEA Clinic, Jonesboro
Heartland Health Institute, Tulsa
TMC Life Research, Houston
West Houston Clinical Research Services, Houston
The Center for Clinical Studies, Webster
DiscoveResearch, Bryan
Urology San Antonio Research, San Antonio
Downtown Women's Healthcare, Denver
Utah Clinical Trials, Salt Lake City
Wasatch Clinical Research, Salt Lake City
Southwest Clinical Research, Albuquerque
Dermatology Research Associates, Los Angeles
Conant Foundation, San Francisco
Northern Claifornia Research, Carmichael
California State University - Chico, Chico
Westover Heights Clinic, Portland
Clinical Trials of America, Eugene
Women's Clinical Research Center, Seattle
Women's Health Research Center, Lawrenceville
Alliance Women's Research, Riverside Park
Lead Sponsor
Graceway Pharmaceuticals, LLC
INDUSTRY